GPC2 and choroid plexus carcinoma: Expression and CNV analyses demonstrated that GPC2 is a highly expressed and copy-number-gained immunotherapeutic target in ETMRs, MBs, choroid plexus carcinomas, H3 WT HGGs, and DMGs.